AU1546101A - Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders - Google Patents
Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disordersInfo
- Publication number
- AU1546101A AU1546101A AU15461/01A AU1546101A AU1546101A AU 1546101 A AU1546101 A AU 1546101A AU 15461/01 A AU15461/01 A AU 15461/01A AU 1546101 A AU1546101 A AU 1546101A AU 1546101 A AU1546101 A AU 1546101A
- Authority
- AU
- Australia
- Prior art keywords
- acetylcholinesterase
- muscular
- treatment
- pharmaceutical compositions
- neuromuscular disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000012440 Acetylcholinesterase Human genes 0.000 title 1
- 108010022752 Acetylcholinesterase Proteins 0.000 title 1
- 208000021642 Muscular disease Diseases 0.000 title 1
- 229940022698 acetylcholinesterase Drugs 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
- 230000003387 muscular Effects 0.000 title 1
- 208000018360 neuromuscular disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL13297299A IL132972A0 (en) | 1999-11-16 | 1999-11-16 | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
| IL132972 | 1999-11-16 | ||
| PCT/IL2000/000763 WO2001036627A2 (en) | 1999-11-16 | 2000-11-16 | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1546101A true AU1546101A (en) | 2001-05-30 |
Family
ID=11073493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU15461/01A Abandoned AU1546101A (en) | 1999-11-16 | 2000-11-16 | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1546101A (en) |
| IL (1) | IL132972A0 (en) |
| WO (1) | WO2001036627A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL143379A (en) * | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Antisense oligonucleotide against the r isophorm of human ache and uses thereof |
| EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| CA2873794A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating smn gene family expression |
| CN104583401A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating ATP2A2 expression |
| US10058623B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating UTRN expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| EA201492116A1 (en) | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2 |
| EP2850188A4 (en) | 2012-05-16 | 2016-01-20 | Rana Therapeutics Inc | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE MULTIGENIC FAMILY OF HEMOGLOBIN |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| EP3271460A4 (en) | 2015-03-17 | 2019-03-13 | The General Hospital Corporation | INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1) |
| CN121204097A (en) * | 2019-05-13 | 2025-12-26 | 宾夕法尼亚大学董事会 | Compositions and methods for acetylcholine receptor chimeric autoantibody receptor cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101600A (en) * | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
| US5932780A (en) * | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
| WO1998026062A2 (en) * | 1996-12-12 | 1998-06-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
-
1999
- 1999-11-16 IL IL13297299A patent/IL132972A0/en unknown
-
2000
- 2000-11-16 WO PCT/IL2000/000763 patent/WO2001036627A2/en not_active Ceased
- 2000-11-16 AU AU15461/01A patent/AU1546101A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001036627A3 (en) | 2001-10-04 |
| WO2001036627A2 (en) | 2001-05-25 |
| IL132972A0 (en) | 2001-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
| AU2604301A (en) | Tnf inhibitors for the treatment of neurological, retinal and muscular disorders | |
| HUP0103839A3 (en) | Use of certain drugs for treating nerve root injury | |
| IL127943A (en) | Pharmaceutical and cosmetic compositions for the treatment of skin disorders | |
| AU6530600A (en) | Use of neurotoxin for treating cardiac muscle disorders | |
| AU4060599A (en) | Pharmaceutical composition for treating or preventing sleep disorders | |
| HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0200275A3 (en) | Seed treatment composition and preparation thereof | |
| AU2001266152A1 (en) | Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them | |
| AU2300001A (en) | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease | |
| AU1546101A (en) | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders | |
| AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
| AU7601400A (en) | Treatment and prevention of hepatic disorders | |
| AU3896900A (en) | Treatment of pain | |
| HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
| HUP0102436A3 (en) | Use of reboxetin for preparation of medicament for nervous disorders | |
| AU7106300A (en) | Treatment of skin disorders | |
| AU4511201A (en) | Compositions and methods for the induction and treatment of retinal detachments | |
| AU2432001A (en) | Treatment of mental conditions including depression | |
| PL347976A1 (en) | Isonipecotamides for the treatment of integrin−mediated disorders | |
| AU2420101A (en) | Method and composition for the treatment of pain | |
| AU2566201A (en) | Compounds and methods for the treatment of pain | |
| HUP0203309A3 (en) | Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them | |
| AU4034800A (en) | Novel compositions and methods for prevention and treatment of protozoal disease | |
| AU2683500A (en) | Compositions for the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |